The global clinical oncology next-generation sequencing market is poised for remarkable expansion, with projections showing a dramatic rise from USD 635 million in 2024 to USD 3,131.5 million by 2034, reflecting an impressive compound annual growth rate (CAGR) of 17.3%. This surge underscores the transformative potential of NGS technology in revolutionizing cancer diagnosis and treatment. …
Tag Archives: Clinical Oncology Next-generation Sequencing Market
Global Clinical Oncology Next-Generation Sequencing Market Poised for Remarkable Growth, Projected to Reach USD 3,131.5 million by 2034
The global clinical oncology next-generation sequencing market is on a rapid growth trajectory, with its size estimated at USD 635 million in 2024. Forecasts indicate that the market is set to surge past USD 3,131.5 million by 2034, reflecting a robust compound annual growth rate (CAGR) of 17.3% from 2024 to 2034. The rise of …
Global Clinical Oncology Next-generation Sequencing Market Predict Valuation to Surpass USD 3,131.5 million by 2034
The global clinical oncology next-generation sequencing market size stands at USD 635 million in 2024 and is anticipated to surpass a valuation of USD 3,131.5 million by 2034. The clinical oncology NGS market expansion is estimated at a CAGR of 17.3% from 2024 to 2034. Precision medicine has gained popularity in oncology, as patients’ unique …
Revolutionizing Cancer Treatment: Clinical Oncology Next-Generation Sequencing Market Set to Surpass US$ 1.14 Billion by 2029
The global clinical oncology next-generation sequencing market is poised for exponential growth, according to a recent market analysis. Estimated at a value of US$ 449.4 million in 2022, this sector is projected to soar to a staggering US$ 1.14 billion by 2029, marking a remarkable Compound Annual Growth Rate (CAGR) of 16.3%. The proliferation of …
Clinical Oncology Next-generation Sequencing Market Aims for US$ 1.14 Billion Valuation by 2029
The clinical oncology next-generation sequencing market share is expected to reach a value of US$ 449.4 million by 2022. Owing to the increasing application of next-generation sequencing (NGS) in clinical oncology for more effective, individualised cancer treatment, the market is anticipated to grow at an astounding 16.3% CAGR from 2022 to 2029, when it will …